Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Measles is resurging mainly because childhood vaccination coverage has slipped below the roughly 95% threshold needed for community protection, letting imported cases ignite sustained outbreaks in under-vaccinated pockets. The 2026 case totals, outbreak locations, hospitalization figures, and age breakdowns are laid out below, along with the specific coverage gaps fueling spread. Because measles is airborne and can linger in a room for up to two hours after an infected person leaves, a high fever, cough, and spreading rash deserve quick attention. Since early measles mimics many ordinary viruses, a free, instant online symptom check can help you clarify what your symptoms suggest and decide whether to call a clinician, isolate, or seek urgent care. There are important nuances around exposure timing and vaccination history, so review the complete answer below rather than this summary alone.
Last reviewed for medical accuracy: 10/01/2026
Why Is Measles Coming Back?
Measles, once on track for global elimination, has been resurging in recent years. After major gains in the early 2000s, reported cases jumped sharply following the COVID-19 pandemic. Understanding why measles is coming back—and what the latest 2026 numbers show—can help families and communities stay protected against this highly contagious disease.
Why Is Measles Coming Back?
Several factors have combined to create gaps in population immunity:
• Disruptions to routine immunization
– During the COVID-19 pandemic, many childhood vaccine programs were delayed or paused.
– Worldwide, an estimated 25 million children missed their first dose of measles vaccine in 2020–21.
• Decline in two-dose coverage
– Measles requires about 95 percent vaccination coverage for herd protection.
– Global first-dose coverage slipped from 86 percent in 2019 to 81 percent in 2021; second-dose coverage also fell.
• Vaccine hesitancy and misinformation
– False claims about vaccine safety have spread online, leading some parents to delay or skip MMR (measles-mumps-rubella) shots.
– Certain communities now have vaccination rates below the 90–95 percent threshold.
• Resumption of travel and mass gatherings
– International travel rebounded in 2022–25, allowing measles to cross borders more easily.
– Large events—festivals, conferences, pilgrimages—can spark outbreaks when unvaccinated people mix.
• Pockets of under-immunized populations
– In many countries, access barriers (remote locations, lack of health centers) still limit vaccination.
– Urban “pockets” of unvaccinated children in wealthy countries have also driven flare-ups.
What the 2026 Numbers Show
Based on the World Health Organization (WHO), the U.S. Centers for Disease Control and Prevention (CDC) and regional agencies, here’s where we stand so far in 2026:
Global Trends (WHO, data through June 2026)
• 16 200 confirmed measles cases reported in 80 countries.
• Down slightly (–15 percent) from 19 000 cases in the same period of 2025, but still nearly double the pre-pandemic level (8 500 in 2019).
• Regional breakdown of 2026 cases:
– Africa: 60 percent
– Southeast Asia: 20 percent
– Europe: 10 percent
– Americas: 5 percent
– Western Pacific: 5 percent
United States (CDC, data Jan – June 2026)
• 270 confirmed cases, up from 180 in Jan – June 2025.
• 32 states reported at least one case.
• Notable clusters: Southern California (45 cases), New York City (30 cases), Texas (25 cases).
• Hospitalizations: About 25 percent of reported cases required inpatient care, mostly in infants under 1 and adults over 30.
Europe (ECDC, Jan – May 2026)
• 1 500 confirmed cases among 20 European Economic Area countries.
• Incidence remains similar to 2025, with small outbreaks in France, Germany and Italy.
• Vaccination coverage for two MMR doses averages 93 percent, but several regions still sit under 90 percent.
Why These Numbers Matter
Measles is one of the most contagious viruses known, with a reproductive number (R₀) of 12–18. That means one infected person can, on average, pass measles to 12–18 others in a susceptible community. Complications can include:
• Pneumonia (the leading cause of measles-related death)
• Encephalitis (brain swelling)
• Severe dehydration and diarrhea
• In rare cases, subacute sclerosing panencephalitis (SSPE), a fatal brain disorder appearing years later
Keeping measles at bay isn’t just about individual health—it’s about protecting infants too young to be vaccinated, people with weakened immune systems, and entire communities.
What You Can Do
• Check your child’s vaccination record. Confirm two doses of MMR by age 6.
• Talk to your family doctor or local health clinic about catch-up shots if you or your children missed doses.
• Maintain high coverage—95 percent or more—for both MMR doses.
• Watch for symptoms (fever, rash, cough, runny nose, red eyes). For a free, online symptom check, using the doctor approved Ubie Symptom Checker, click here.
• Keep measles on your radar if you travel internationally or attend large gatherings—ask about a booster if you’re unsure of your status.
Where to Find Credible Information
• World Health Organization (WHO) measles updates
• Centers for Disease Control and Prevention (CDC) measles page
• European Centre for Disease Prevention and Control (ECDC) measles surveillance reports
Bottom Line
Measles is making an unwelcome comeback because of immunity gaps left by pandemic disruptions, persistent vaccine hesitancy, and renewed global travel. The 2026 data show that, while some progress has returned, case counts remain above pre-COVID levels. The good news is that we have a safe, effective vaccine—and strong community immunity can stamp out outbreaks.
If you have symptoms that concern you or think you may have been exposed, speak to a doctor about anything that could be life threatening or serious. Talk to your healthcare provider about vaccination, and consider using the Ubie Symptom Checker to help guide you on next steps. Measles today need not be measles tomorrow—together, we can close the immunity gap.
(References)
* Hurd RH, Somaza BA. "Rubeola: an atypical case". Nebr Med J. 1991 Jul;76(7):198-200. PMID: 1881479.
* Lehel F, Tóth I, Bíró Z, Szent-Andrássy T, Réthy M, Vanger S. [Incidence of fetal damage after the 1978-79 measles epidemic in northeastern Hungary]. Orv Hetil. 1984 Nov 18;125(47):2863-70. PMID: 6504521.
* Rota JS, Heath JL, Rota PA, King GE, Celma ML, Carabaña J, Fernandez-Muñoz R, Brown D, Jin L, Bellini WJ. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J Infect Dis. 1996 Jan;173(1):32-7. doi: 10.1093/infdis/173.1.32. PMID: 8537679.
* Coughlan S, Connell J, Cohen B, Jin L, Hall WW. Suboptimal measles-mumps-rubella vaccination coverage facilitates an imported measles outbreak in ireland. Clin Infect Dis. 2002 Jul 1;35(1):84-6. doi: 10.1086/340708. Epub 2002 Jun 6. PMID: 12060880.
* ORLANDINI M. [Clinical and etiopathogenetic considerations on a case of acute morbillous meningoencephalitis, contemporaneously verified in an epidemic resurgence of Marchesian Coxsackie meningoneuraxitis]. Minerva Med. 1956 Dec 15;47(100):2053-6. PMID: 13399914.
* Zandotti C, Jeantet D, Lambert F, Waku-Kouomou D, Wild F, Freymuth F, Harle JR, de Lamballerie X, Charrel RN. Re-emergence of measles among young adults in Marseilles, France. Eur J Epidemiol. 2004;19(9):891-3. doi: 10.1023/b:ejep.0000040453.13914.48. PMID: 15499900.
* Magurano F, Baggieri M, Bordi L, Lalle E, Chironna M, Lazzarotto T, Amendola A, Baldanti F, Ansaldi F, Filia A, Declich S, Iannazzo S, Pompa MG, Bucci P, Marchi A, Nicoletti L. Measles in Italy: Co-circulation of B3 variants during 2014. J Med Virol. 2016 Jun;88(6):1081-5. doi: 10.1002/jmv.24416. Epub 2015 Nov 6. PMID: 26496509.
* Heavey E, Peterson K. Rubeola update for nurses. Nursing. 2019 Feb;49(2):15-17. doi: 10.1097/01.NURSE.0000552706.03868.c6. PMID: 30676551.
* Yamakawa M, Tokinobu A, Tanaka Y, Matsushita N, Hashizume M. Missed opportunities for measles vaccination among departing travelers from Japan to India. J Travel Med. 2020 Feb 3;27(1). doi: 10.1093/jtm/taz086. PMID: 31728514.
* Emanuele P. Measles (Rubeola) 2019. Workplace Health Saf. 2020 Feb;68(2):104. doi: 10.1177/2165079919890354. PMID: 31910782.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.